Galectin-3, a β-galactoside-binding lectin, is upregulated in several metabolic disorders, such as obesity and diabetes, by disrupting the insulin signaling pathways in insulin-responsive organs, therefore playing a role in the pathogenesis of T2DM. This evidence concerns the gene LGALS3 and type 2 diabetes mellitus.